{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T15:59:57Z","timestamp":1791734397688,"version":"4.3.4"},"reference-count":90,"publisher":"Informa UK Limited","issue":"15","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine"],"published-print":{"date-parts":[[2026,8,3]]},"DOI":"10.1080\/17435889.2026.2705388","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:41:45Z","timestamp":1784536905000},"page":"2291-2310","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Navigating the translational Valley of death in oncology nanotheranostics: manufacturing, biological, clinical, and regulatory barriers to implementation"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4105-8615","authenticated-orcid":false,"given":"Esther Ugo","family":"Alum","sequence":"first","affiliation":[{"name":"Kampala International University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Chukwu","family":"Obasi","sequence":"additional","affiliation":[{"name":"David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]},{"name":"David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Uzor","sequence":"additional","affiliation":[{"name":"David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Obinna","family":"Eji","sequence":"additional","affiliation":[{"name":"Alex Ekwueme Federal University Ndufu-Alike Ikwo","place":["Abakaliki, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emenike Benjamin","family":"Amadi","sequence":"additional","affiliation":[{"name":"David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akunna Perpetua","family":"Emeruwa","sequence":"additional","affiliation":[{"name":"David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]},{"name":"David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada Ak.","family":"Akwari","sequence":"additional","affiliation":[{"name":"David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]},{"name":"David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prince Nkemakolam","family":"Okoroh","sequence":"additional","affiliation":[{"name":"David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]},{"name":"David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugonna Cassandra","family":"Aniokete","sequence":"additional","affiliation":[{"name":"David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]},{"name":"David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict Nnachi","family":"Alum","sequence":"additional","affiliation":[{"name":"Kampala International University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01262-3"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.126057"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2022.12.001"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01536-y"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-016-1958-5"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00790"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1039\/D2RA07863E"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-023-00581-x"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.7150\/ntno.64141"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082256"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chempr.2025.102706"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-024-01754-7"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/natrevmats.2016.14"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030893"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S88023"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/21691401.2018.1552595"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02133-1"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0785"},{"key":"e_1_3_6_23_1","unstructured":"Aetna. Irinotecan liposome injection (onivyde): medical clinical policy bulletin. [cited 2026 Jul 6]. Available from: https:\/\/www.aetna.com\/cpb\/medical\/data\/900_999\/0902.html"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131429"},{"key":"e_1_3_6_25_1","unstructured":"National Institutes of Health. Doxorubicin hydrochloride liposomal: patient drug record. [cited 2026 Jul 6]. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/drugs\/doxorubicin-hydrochloride-liposomal\/patient"},{"key":"e_1_3_6_26_1","unstructured":"U.S. Food and Drug Administration. ONIVYDE (irinotecan liposome injection) prescribing information. [cited 2026 Jul 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/207793s018lbl.pdf"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2990"},{"key":"e_1_3_6_28_1","unstructured":"European Medicines Agency. Vyxeos liposomal (previously vyxeos): EPAR. [cited 2026 Jul 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vyxeos-liposomal"},{"key":"e_1_3_6_29_1","unstructured":"Jazz Pharmaceuticals. Phase III multicenter randomized trial of CPX-351 (cytarabine: daunorubicin) liposome injection versus cytarabine and daunorubicin in patients 60\u201375 years of age with untreated high-risk (secondary) AML. ClinicalTrials.gov. 2020. [cited 2026 Jul 6]. Available from: https:\/\/clinicaltrials.gov\/"},{"key":"e_1_3_6_30_1","unstructured":"Novartis. Lutathera product information. [cited 2026 Jul 6]. Available from: http:\/\/view.ceros.com\/novartis\/lut-hero-v3"},{"key":"e_1_3_6_31_1","unstructured":"Center for Drug Evaluation and Research. FDA expands Pluvicto\u2019s metastatic castration-resistant prostate cancer indication. U.S. Food and drug administration. 2025. [cited 2026 Jul 6]. Available from https:\/\/www.fda.gov\/"},{"key":"e_1_3_6_32_1","unstructured":"Endocyte. VISION: an international prospective open-label multicenter randomized phase 3 study of 177Lu-PSMA-617 in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer. ClinicalTrials.gov. 2024. [cited 2026 Jul 6]. Available from https:\/\/clinicaltrials.gov\/"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph12030114"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2875"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30326-2"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/1091581815600170"},{"key":"e_1_3_6_37_1","unstructured":"Nanobiotix. A multicenter randomized open-label phase II\/III study to compare the efficacy of NBTXR3 implanted as intratumor injection and activated by radiotherapy versus radiotherapy alone in patients with locally advanced soft tissue sarcoma of the extremity and trunk wall. ClinicalTrials.gov. 2021. [cited 2026 Jul 6]. Available from https:\/\/clinicaltrials.gov\/"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1906929116"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1411393111"},{"key":"e_1_3_6_40_1","unstructured":"Calando Pharmaceuticals. A phase I dose-escalating study of the safety of intravenous CALAA-01 in adults with solid tumors refractory to standard-of-care therapies. ClinicalTrials.gov. 2013. [cited 2026 Jul 6]. Available from https:\/\/clinicaltrials.gov\/"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.113073"},{"key":"e_1_3_6_42_1","unstructured":"NewLink Genetics Corporation. A phase 1b\/2a safety and pharmacokinetic study of CRLX101 (formerly named IT-101) in the treatment of advanced solid tumors. ClinicalTrials.gov. 2020. [cited 2026 Jul 6]. Available from https:\/\/clinicaltrials.gov\/"},{"key":"e_1_3_6_43_1","unstructured":"UNC Lineberger Comprehensive Cancer Center. Phase Ib\/II study of neoadjuvant chemoradiotherapy with CRLX-101 and capecitabine for locally advanced rectal cancer. ClinicalTrials.gov. 2020. [cited 2026 Jul 6]. Available from https:\/\/clinicaltrials.gov\/"},{"key":"e_1_3_6_44_1","unstructured":"NewLink Genetics Corporation. A phase Ib\/II study of CRLX101 in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian fallopian tube or primary peritoneal cancer. ClinicalTrials.gov. 2026. [cited 2026 Jul 6]. Available from https:\/\/clinicaltrials.gov\/"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009524"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1936"},{"key":"e_1_3_6_47_1","unstructured":"Center for Drug Evaluation and Research. Drug products including biological products that contain nanomaterials: guidance for industry. U.S. Food and Drug Administration. [cited 2026 Jul 6]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/drug-products-including-biological-products-contain-nanomaterials-guidance-industry"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/nano8050311"},{"key":"e_1_3_6_49_1","unstructured":"European Medicines Agency. ICH Q8(R2) pharmaceutical development: scientific guideline. [cited 2026 Jul 6]. Available from: https:\/\/www.ema.europa.eu\/en\/ich-q8-r2-pharmaceutical-development-scientific-guideline"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00657-y"},{"key":"e_1_3_6_51_1","unstructured":"U.S. Food and Drug Administration. Q9(R1): quality risk management: guidance for industry. [cited 2026 Jul 6]. Available from: https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-9918662281906676-pdf"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0090-8"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12668-025-01980-w"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.11.012"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2026.101166"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-023-00552-2"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114621"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2017.61"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316759"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c05922"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44222-025-00321-6"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1080\/17435889.2025.2538423"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24183283"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122899"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011279"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1800213"},{"key":"e_1_3_6_67_1","unstructured":"Hennig M. Nanotechnology-based medicinal products for human use: EMA report. Pharma excipients. 2025. [cited 2026 Jul 6]. Available from: https:\/\/www.pharmaexcipients.com\/news\/nanotechnology-human-use\/"},{"key":"e_1_3_6_68_1","unstructured":"Office of the Commissioner. Frequently asked questions about combination products. U.S. Food and drug administration. 2022. [cited 2026 Jul 6]. Available from https:\/\/www.fda.gov\/"},{"key":"e_1_3_6_69_1","unstructured":"Electronic Code of Federal Regulations. CFR part 3 - product jurisdiction. 2021. [cited 2026 Jul 6]. Available from: https:\/\/www.ecfr.gov\/current\/title-21\/part-3"},{"key":"e_1_3_6_70_1","unstructured":"European Medicines Agency. Data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product: scientific guideline. [cited 2026 Jul 6]. Available from: https:\/\/www.ema.europa.eu\/en\/data-requirements-intravenous-iron-based-nano-colloidal-products-developed-reference-innovator-medicinal-product-scientific-guideline"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00508"},{"key":"e_1_3_6_72_1","unstructured":"European Medicines Agency. Multidisciplinary guidelines: nanomedicines. [cited 2026 Jul 6]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-guidelines\/multidisciplinary-guidelines\/multidisciplinary-guidelines-nanomedicines"},{"key":"e_1_3_6_73_1","unstructured":"International Pharmaceutical Regulators Programme. Nanomedicines working group. [cited 2026 Jul 6]. Available from https:\/\/www.iprp.global\/working-group\/nanomedicines-0"},{"key":"e_1_3_6_74_1","unstructured":"Center for Drug Evaluation and Research. Q9(R1) quality risk management. U.S. Food and drug administration. [cited 2026 Jul 6]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/q9r1-quality-risk-management"},{"key":"e_1_3_6_75_1","unstructured":"European Medicines Agency. ICH Q10 pharmaceutical quality system: scientific guideline. [cited 2026 Jul 6]. Available from: https:\/\/www.ema.europa.eu\/en\/ich-q10-pharmaceutical-quality-system-scientific-guideline"},{"key":"e_1_3_6_76_1","unstructured":"International Pharmaceutical Regulators Programme. Nanomedicines. [cited 2026 Jul 6]. Available from https:\/\/www.iprp.global\/working-group\/nanomedicines-0"},{"key":"e_1_3_6_77_1","unstructured":"European Medicines Agency. International coalition of Medicines regulatory authorities (ICMRA). [cited 2026 Jul 6]. Available from: https:\/\/www.ema.europa.eu\/en\/partners-networks\/international-activities\/multilateral-coalitions-initiatives\/international-coalition-medicines-regulatory-authorities-icmra"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2019.02.008"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-024-01646-2"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c07840"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S529003"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00278"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067975"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.3390\/jnt6010004"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1080\/17435889.2025.2520736"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.3390\/jnt5040014"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01977-1"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2023.2219868"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25040825"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1039\/c9ra09021e"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122391"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-022-00859-0"}],"container-title":["Nanomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17435889.2026.2705388","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17435889.2026.2705388","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17435889.2026.2705388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:32:00Z","timestamp":1787574720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17435889.2026.2705388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":90,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,8,3]]}},"alternative-id":["10.1080\/17435889.2026.2705388"],"URL":"https:\/\/doi.org\/10.1080\/17435889.2026.2705388","relation":{},"ISSN":["1743-5889","1748-6963"],"issn-type":[{"value":"1743-5889","type":"print"},{"value":"1748-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=innm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=innm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}